Protocol Ledger

NCT06399289 · Phase III · COMPLETED

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

Interventional Phase III clinical trial protocol NCT06399289 sponsored by CSL Behring in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-28 Enrollment: 23 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06399289
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)23 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06399289
Protocol FieldVerified Registry Value
NCT IdentifierNCT06399289
Consolidated Lead SponsorCSL Behring
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment23 participants (ACTUAL)
Registered Start Date2024-07-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06399289
Hospital Research SiteLocationSite Profile
Nanfang Hospital of Southern Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Jinan Central HospitalJinan, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for CSL Behring across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI